The initial studies mainly investigated the clinical efficacy and safety of anti-PD1/PDL1 therapy for non-specific cancer, and subsequently compared anti-PD1/PDL1 therapy with anti-CTLA4 antibodies and targeted therapies for melanoma. The gene discussed is CTLA4; the disease is cancer.